Manufacturers can support the ICD-10 transition

Despite continued rumblings of uncertainty surrounding the implementation of ICD-10, pharmaceutical manufacturers should continue preparing to reduce the risk for provider claims challenges, payer errors, and other access concerns that could compromise continuity of therapy. While healthcare facilities and physician […]

Read More

Building a cold-chain data network

FedEx’s SenseAware device One of the longstanding essentials of transporting temperature-sensitive pharma products has been documenting the conditions experienced during a shipment: usually, the temperature of the product payload; increasingly, conditions such as humidity, the status of containers holding the […]

Read More

2015 PDMA Sharing Conference

Back in the day—the year 1990. Heading into the last decade of the 20th century, George H.W. Bush was in office presiding over Operation Desert Storm. The first webpage was written on the World Wide Web. Microsoft released Windows 3.0 […]

Read More

The Phase III pricing experiment

Phase III, as we all know, is the last step before a drug is submitted to FDA for approval; if FDA okays it at that point, it comes to market as soon as the drug sponsor can make the commercialization […]

Read More

Moving the needle on diabetes

Merck’s Januvia There are powerful therapies from the pharma industry to combat diabetes, but it continues to be a challenge to public health in the US, and to societies around the world moving up the ladder from developing to developed. […]

Read More

Product launch–the 21st-century way

The classic view of new product launches in the pharma/biotech industries has been similar to a Broadway theater opening: all the performance details have been worked out, a splashy promotional effort has been made, and, on opening night, the critics […]

Read More

Get better at managing clinical trial financials

Today’s clinical trial landscape is saturated with vendor-outsourced trials, generating multimillion-dollar program budgets for sponsors. The constant reported budget swings and cost overruns puzzle senior leadership. What is so difficult about forecasting and managing trial budgets? Due to the inherent […]

Read More